SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reported record-high monthly and quarterly delivery numbers, sparking enthusiasm about the company's growth. Community discussions revolve around the significant year-over-year increase in deliveries and the potential impact of new models like Onvo and Firefly. Some investors express optimism about NIO's future, while others focus on its valuation relative to competitors in the EV sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the token's vision of merging cryptocurrency with green culture, emphasizing growth, freedom, and innovation within the digital space. Discussions highlight Weedcoin as more than just a digital currency, but as a symbol of a cultural movement and a key to unlocking future opportunities. The community expresses strong conviction and promotes Weedcoin as a force that shapes the digital landscape.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending after reports of a U.S. government equity stake, signaling strong support for domestic lithium production. The community is buzzing about a potential short squeeze and the stock's long-term prospects, drawing comparisons to government-backed runs of $MP and $INTC. Investors view this as a bullish sign for the company's Thacker Pass project and its role in securing the U.S. lithium supply chain.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as a government shutdown looms, triggering volatility and uncertainty. Community members are debating whether the shutdown is already priced in, with some anticipating a potential dip while others expect a market rally similar to past shutdowns. Overall sentiment is mixed, with both bullish and bearish arguments circulating, focusing on historical patterns and potential economic impacts.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu.X is trending as the community rallies around its strong IRL presence and expanding ecosystem, including Kendu Energy drink and other branded products.  Enthusiasm is high as the holder count approaches 19,000, with community members emphasizing that the project combines a high degree of decentralization with a high share of diamond hand holders and a tireless work ethic.

Aventus Network

Aventus Network ($AVT.X) is trending due to its strong chart setup, real-world partnerships (Vodafone, Heathrow Airport, Polkadot) and potential for a breakout. Community members believe the token is undervalued, highlighting its low market cap and integration with Polkadot as catalysts for significant upside. Traders are closely monitoring volume as a key indicator for potential price movement.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to earnings, with community chatter focused on revenue growth and turnaround efforts despite tariff concerns. Discussions include both bullish and bearish outlooks, with some anticipating a move towards $80 while others foresee a drop. The brand's collaboration with SKIMS and the impact of global factors like China sales and potential government shutdowns are also being closely monitored.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to recent unaudited financial results showing positive EPS, sparking discussions about its low float and potential for a short squeeze. The community is actively watching key resistance levels and anticipating further upward movement. Some traders highlight the possibility of a share offering and caution around the stock's historical volatility and association with Chinese companies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, creating market uncertainty. The community is debating the potential impact, with some anticipating a pullback while others believe a deal will be reached, leading to a rally. Discussions also involve broader market dynamics, such as the influence of a few mega-cap stocks and end-of-quarter window dressing.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to recent price movement, with community members actively discussing potential breakouts and short squeezes, given the stock's low float. Traders are watching key resistance levels, anticipating further upward momentum if these levels are breached. Some traders are expressing concern over potential pump and dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated with its Revita lost an additional 2.5% of their total body weight at three months in a trial. At the time of writing, shares of the company traded 28% higher on Friday afternoon.The study was designed to evaluate the Revita procedure in adults with obesity who achieved at least 15% total body weight loss with Tirzepatide, the active ingredient in Eli Lilly’s blockbuster weight loss drug Zepbound. Those who received a sham procedure after discontinuing Zepbound regained 10% total body weight in the study at three months, the company said.Revita is Fractyl’s lead product candidate. The procedure is designed to reverse damage to intestinal nutrient-sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets by remodeling the inner wall of the first part of the small intestine.“These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible,” the company said, while adding that the study also supports Revita in post-GLP-1 weight maintenance.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156942/0/en/Fractyl-Health-Announces-Groundbreaking-Data-from-REMAIN-1-Midpoint-Cohort-Showing-Revita-Maintained-Weight-Loss-After-GLP-1-Discontinuation.html">stated</a> that no serious adverse events related to Revita were identified in the study, and side effects were infrequent and mild. The firm expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.On Friday, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156951/0/en/Fractyl-Health-Announces-Pricing-of-60-Million-Underwritten-Offering-of-Common-Stock.html">announced</a> the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, representing a discount of about 1% from the stock’s closing price on Thursday. The gross proceeds from the offering are expected to be about $60 million, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GUTS">GUTS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_00_54_PM_png_90a4342a59.webp" alt="GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment at the offering.<stembedurl>https://stocktwits.com/Stmkr/message/630122910</stembedurl>GUTS stock is down 38% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GUTS Stock Rallied About 28% Today – Here’s Why

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.

Equity

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.


Fractyl Health shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants.&nbsp;The offering includes accompanying common warrants, and Ladenburg Thalmann is acting as&nbsp;the sole book-running manager.Despite the market’s negative reaction to the capital raise, retail sentiment on Stocktwits remained optimistic, buoyed&nbsp;by the release of strong new clinical data hours earlier.&nbsp;The company shared two-year follow-up results from the Germany Real-World Registry study, which evaluated the Revita procedure in people with obesity and advanced type 2 diabetes (T2D) who had inadequately controlled glucose levels despite being on up to three glucose-lowering agents (GLAs).According to the study, a single Revita procedure led to a median weight loss of 9.6%, sustained over two years, with weight decreasing from 104 kg to 97 kg at year one and remaining stable through year two.&nbsp;Notably, 7 of 8 participants achieved at least a 5% weight reduction, and 5 of 8 saw reductions of 10% or more. Only one participant, who had a history of cortisone therapy known to cause weight gain, experienced&nbsp;a modest weight increase.Meanwhile, median HbA1c decreased from 9.6% to 7.2%, which was maintained over two years of follow-up. Patients were also able to reduce or stabilize the dosing of GLAs, and there were no device or procedure-related serious adverse events.Fractyl said the findings support the potential of Revita as a long-lasting, non-drug metabolic therapy and build momentum for its ongoing U.S. pivotal trial, REMAIN-1, which is under an IDE and is designed to assess Revita for weight maintenance after GLP-1 treatment.&nbsp;The company expects Midpoint Cohort data in the third quarter and primary endpoint data from the Pivotal Cohort in the second half of&nbsp; 2026.As of now, 34 patients are enrolled in the Germany registry, which is no longer recruiting but will continue with protocol-defined follow-up. Weight loss and glycemic benefits were observed as early as one month post-procedure and persisted throughout the study duration.Fractyl intends to use net proceeds from the offering, along with existing cash, to support both the Revita and Rejuva pipeline programs, and for working capital and general corporate purposes.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">retail sentiment for Fractyl</a> was ‘extremely bullish’ amid a 124% surge in 24-hour message volume.One user said the strong two-year Revita data was a “big win” and that similar setups, including positive clinical news followed by a quick offering, have historically seen shares recover to pre-offering levels.&nbsp;While the user noted the company “could have done the PR’ing/offering a bit better,” they added the underlying science was “phenomenal” and called Revita a “first-in-class” product with major potential.<stembedurl>https://stocktwits.com/BioRich/message/623885253</stembedurl>Another user said they were buying into Fractyl, looking for either a short squeeze or a potential buyout.<stembedurl>https://stocktwits.com/garygb/message/623881828</stembedurl>Fractyl’s stock has declined 12.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Fractyl Health (GUTS) shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants. (Photo credit: Getty Images)

Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data

Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health Receives FDA IDE Approval for the Revita  Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study

Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTS  Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...

Fractyl Health announces results from Rejuva platform

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GUTS News

GUTS Fractyl Health Inc.